Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

Lancet Neurology
Emily J HendersonYoav Ben-Shlomo

Abstract

Falls are a frequent and serious complication of Parkinson's disease and are related partly to an underlying cholinergic deficit that contributes to gait and cognitive dysfunction in these patients. Gait dysfunction can lead to an increased variability of gait from one step to another, raising the likelihood of falls. In the ReSPonD trial we aimed to assess whether ameliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability. We did this randomised, double-blind, placebo-controlled, phase 2 trial at the North Bristol NHS Trust Hospital, Bristol, UK, in patients with Parkinson's disease recruited from community and hospital settings in the UK. We included patients who had fallen at least once in the year before enrolment, were able to walk 18 m without an aid, had no previous exposure to an acetylcholinesterase inhibitor, and did not have dementia. Our clinical trials unit randomly assigned (1:1) patients to oral rivastigmine or placebo capsules (both taken twice a day) using a computer-generated randomisation sequence and web-based allocation. Rivastigmine was uptitrated from 3 mg per day to the target dose of 12 mg per day over 12 weeks. Both the trial team and patien...Continue Reading

References

Aug 1, 1990·Journal of the Neurological Sciences·O BlinG Serratrice
Oct 1, 1994·Brain : a Journal of Neurology·M E MorrisJ J Summers
Apr 1, 1994·Archives of Physical Medicine and Rehabilitation·M E FeltnerJ L McNitt-Gray
Dec 10, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·G K WenningI Litvan
Jan 19, 2000·Archives of Physical Medicine and Rehabilitation·J M Bond, M Morris
Nov 27, 2002·The Gerontologist·Margaret SchenkmanKathryn Whetten-Goldstein
Jul 2, 2003·Journal of Biomechanics·Tammy M Owings, Mark D Grabiner
Mar 17, 2004·Controlled Clinical Trials·Heejung BangClarence E Davis
Jun 4, 2005·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·M Clare RobertsonPeter Herbison
Sep 3, 2005·Journal of the American Geriatrics Society·Sarah E LambUNKNOWN Prevention of Falls Network Europe and Outcomes Consensus Group
Sep 24, 2009·Brain : a Journal of Neurology·M U FerrayeP Pollak
Jul 16, 2010·The Journal of Clinical Investigation·Carine KarachiChantal François
Oct 18, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·Monika Pötter-Nerger, Jens Volkmann
Feb 4, 2014·Parkinsonism & Related Disorders·Marjolein A van der MarckUNKNOWN NPF Falls Task Force
Jan 2, 2015·Neurology·Colleen G CanningVictor S C Fung

❮ Previous
Next ❯

Citations

May 8, 2016·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Vijay R VarmaMichelle C Carlson
Feb 27, 2016·Neuroscience and Biobehavioral Reviews·Rosie MorrisLynn Rochester
Oct 28, 2016·Expert Opinion on Pharmacotherapy·Santiago Perez-LloretFrancisco J Barrantes
Feb 23, 2017·Journal of Parkinson's Disease·Lorena R S AlmeidaJamary Oliveira-Filho
May 5, 2017·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Rosie MorrisLynn Rochester
Jan 25, 2017·Neuroscience and Biobehavioral Reviews·Qu TianStephanie A Studenski
Oct 13, 2017·Journal of Occupational and Environmental Medicine·Sunwook KimThomas A Arcury
Mar 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxUNKNOWN Movement Disorder Society Evidence-Based Medicine Committee
Feb 13, 2018·The European Journal of Neuroscience·Samuel StuartLynn Rochester
Apr 7, 2018·Current Neurology and Neuroscience Reports·Bettina DebûElena Moro
Apr 15, 2018·Current Neurology and Neuroscience Reports·H Ben-PaziUNKNOWN International Parkinson and Movement Disorder Society Telemedicine Task Force
Oct 27, 2017·Movement Disorders : Official Journal of the Movement Disorder Society·Alfonso FasanoLynn Rochester
May 19, 2018·Disability and Rehabilitation·Sophia HulbertAnn Ashburn
Aug 5, 2017·Pharmacogenomics·Katja Susanne JustJürgen Brockmöller
Jul 25, 2018·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·I V Miliukhina, E V Gracheva
Oct 12, 2017·PloS One·Johannes C M SchlachetzkiJochen Klucken
Dec 20, 2018·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M Montero-OdassoS W Muir-Hunter
Jan 21, 2019·Clinical Pharmacology and Therapeutics·Kirsten E ZeunerDaniela Berg
Aug 14, 2018·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Manuel Montero-OdassoUNKNOWN Canadian Gait and Cognition Network
Jan 6, 2018·Nature Reviews. Neurology·Walter Maetzler, Daniela Berg
Jun 22, 2019·Journal of Neural Transmission·I CsotiU Wüllner
Jan 11, 2018·Journal of the American Geriatrics Society·Manuel Montero-Odasso, Mark Speechley
Aug 17, 2019·Expert Review of Neurotherapeutics·Martijn L T M MüllerNicolaas I Bohnen
Oct 3, 2019·Expert Review of Neurotherapeutics·Matthew J BarrettKathryn L Holloway
Aug 28, 2019·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Stephen JozaFang Ba
Sep 25, 2019·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ríona Mc ArdleLynn Rochester
Sep 29, 2017·Neurology·Caroline MoreauDavid Devos
Mar 22, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Per SvenningssonUNKNOWN IRL752 Collaborators
May 31, 2019·Journal of Neurology, Neurosurgery, and Psychiatry·Andrea PilottoAristide Merola
May 3, 2020·International Journal of Molecular Sciences·Ramon Cacabelos
May 26, 2018·Global Advances in Health and Medicine : Improving Healthcare Outcomes Worldwide·Gloria Vergara-DiazPeter M Wayne
Jun 11, 2020·Expert Opinion on Drug Metabolism & Toxicology·Ramón Cacabelos
Aug 25, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Samuel StuartMartina Mancini
Jun 9, 2016·Movement Disorders : Official Journal of the Movement Disorder Society·Walter MaetzlerMalcolm Horne
Apr 27, 2018·Frontiers in Neuroscience·James J FitzGeraldChrystalina A Antoniades
Apr 27, 2018·Age and Ageing·Stephen R Lord, Jacqueline C T Close

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.